News
![Here's Why Alnylam Pharmaceuticals, Inc. Is Slipping Today](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Here's Why Alnylam Pharmaceuticals, Inc. Is Slipping Today
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) a clinical-stage biotech developing RNA-based therapies to treat rare diseases, announced an immediate halt to all studies with one of the....
![Here's Why Cara Therapeutics Rose 9.6% in August](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Here's Why Cara Therapeutics Rose 9.6% in August
Cara Therapeutics (NASDAQ: CARA), a clinical-stage biotech focused on drugs that relieve pain, rose by nearly 10% during August, according to data from S&P Global Market Intelligence. The jump....
![5 Things You'll Want to Know From Celgene Corporation's Latest Presentation](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
5 Things You'll Want to Know From Celgene Corporation's Latest Presentation
It's been a busy week for biotech and healthcare conferences. Drugmakers big and small have been making the rounds, answering questions about their current status and future prospects. Celgene....
![5 Key Things You Should Watch With Jazz Pharmaceuticals](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
5 Key Things You Should Watch With Jazz Pharmaceuticals
It's been a great year for Jazz Pharmaceuticals (NASDAQ: JAZZ) shareholders so far. The biotech stock is up more than 35% year to date. However, most of those gains were made in the first....
![5 Things Gilead Sciences' Management Just Said That You'll Want to Know](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
5 Things Gilead Sciences' Management Just Said That You'll Want to Know
Last week, Gilead Sciences (NASDAQ: GILD) generated plenty of buzz with the announcement of its planned acquisition of Kite Pharma (NASDAQ: KITE). On Wednesday, several of the company's top....
![Evotec: Gute News zum Handelsstart](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Evotec: Gute News zum Handelsstart
Der Wirkstoffhersteller Evotec meldet heute vorbörslich den Abschluss einer neuen Forschungs-Kooperation. Zusammen mit ABIVAX soll am französischen Standort im Bereich „Behandlung von schweren....
![Here's Why Spark Therapeutics Inc. Surged 23.5% in August](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Here's Why Spark Therapeutics Inc. Surged 23.5% in August
Shares of Spark Therapeutics Inc. (NASDAQ: ONCE), a clinical-stage biotech developing gene therapies, rose 23.5% in August, according to data from S&P Global Market Intelligence. The company....
![Here's What Lifted bluebird bio Inc. Stock 40% Higher in August](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Here's What Lifted bluebird bio Inc. Stock 40% Higher in August
Shares of bluebird bio Inc. (NASDAQ: BLUE), a clinical-stage biotech developing cell-based therapies, soared 40% in August, according to data from S&P Global Market Intelligence. A generous....
![Why Kite Pharma Soared 64.8% in August](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Why Kite Pharma Soared 64.8% in August
Shares of Kite Pharma (NASDAQ: KITE), a clinical-stage biotech focused on chimeric antigen receptor T-cell (CAR-T therapy), skyrocketed 65% in August, according to data from S&P Global Market....
![Here's Why Voyager Therapeutics Gained as Much as 24.9% Today](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Here's Why Voyager Therapeutics Gained as Much as 24.9% Today
Shares of clinical-stage biopharma Voyager Therapeutics (NASDAQ: VYGR) popped nearly 25% today after the company announced positive results for a phase 1b trial investigating the potential of its....
![Why Sarepta Therapeutics Stock Is Rising Today](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Why Sarepta Therapeutics Stock Is Rising Today
Shares of mid-cap biotech Sarepta Therapeutics (NASDAQ: SRPT) marched almost 11% higher Wednesday morning on elevated volume. The stock's rally was catalyzed by news of encouraging results from an....
![Here's Why Novo Nordisk A/S Gained 12% in August](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Here's Why Novo Nordisk A/S Gained 12% in August
Shares of Danish pharma giant Novo Nordisk A/S (NYSE: NVO) rose 11.7% in August, according to data from S&P Global Market Intelligence. Investors were relieved to see that the sales stall the....
![Upcoming Data Releases Fueled Strong Gains in These 2 Marijuana Stocks Last Week](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Upcoming Data Releases Fueled Strong Gains in These 2 Marijuana Stocks Last Week
Though speculators' eyes may be on bitcoin and other cryptocurrencies at the moment, arguably no group of stock-based equities has been stronger over the trailing year than marijuana stocks. If we....
![Could These 2 Biotech Stocks Really Double Your Money?](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Could These 2 Biotech Stocks Really Double Your Money?
Investment-bank analysts have been slapping lofty price targets on small-cap biotech stocks recently. More than a few targets I've seen recently suggest you could easily double your money or....
![7 Medical Conditions That Will Be Lining Big Pharma's Pockets by 2020](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
7 Medical Conditions That Will Be Lining Big Pharma's Pockets by 2020
Image source: Getty Images.Imagine a stack of dollar bills reaching from the ground to more than 95,000 miles into the sky -- nearly four-tenths of the way to the moon. That stack would total $1.4....
![What's Behind Mallinckrodt's 12.2% Tumble Today](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
What's Behind Mallinckrodt's 12.2% Tumble Today
Growing concern that generic alternatives to one of its best-selling drugs could threaten future sales and that an investigation into the marketing of opioid pain medication could create headwinds....
![Why Exact Sciences Shares Rallied 10.2% in August](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Why Exact Sciences Shares Rallied 10.2% in August
After the company reported better-than-expected top- and bottom-line second-quarter results in late July and updated investors on its strategy at Cannacord's 37th annual growth conference on Aug.....
![Here's Why Cellectis SA Fell as Much as 31.6% Today](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Here's Why Cellectis SA Fell as Much as 31.6% Today
Shares of biopharma Cellectis (NASDAQ: CLLS) fell nearly 32% today after the company announced that the U.S. Food and Drug Administration had placed a clinical hold on its second leading product....
![Quantum Genomics Receives FDA Clearance of IND Application for QGC001](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Quantum Genomics Receives FDA Clearance of IND Application for QGC001
Company to Launch NEW-HOPE, a targeted Phase II clinical trial in Hypertension in the U.S.
Paris & New York, September 5, 2017
Quantum Genomics (Euronext Growth − FR0011648971 − ALQGC;....
![Quantum Genomics reçoit l'accord de la FDA pour le lancement de l'étude NEW-HOPE de phase II aux Etats-Unis dans l'hypertension artérielle](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Quantum Genomics reçoit l'accord de la FDA pour le lancement de l'étude NEW-HOPE de phase II aux Etats-Unis dans l'hypertension artérielle
Paris, le 5 septembre 2017
Quantum Genomics (Euronext Growth − FR0011648971 − ALQGC), société biopharmaceutique dont la mission est de développer de nouvelles thérapies pour des besoins....
![Here's Why Insmed Incorporated Is Skyrocketing](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Here's Why Insmed Incorporated Is Skyrocketing
Investors in Insmed (NASDAQ: INSM) are having an incredible start to the short trading week. Shares of the rare disease focused biotech are up 110% as of 11:15 a.m. EDT, after the company....
![The Key Reason Incyte Corporation Added $850 Million in Market Cap in August](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
The Key Reason Incyte Corporation Added $850 Million in Market Cap in August
Shares of Incyte (NASDAQ: INCY), a large-cap biotech company primarily focused on developing therapies to treat cancer and inflammatory diseases, tacked on more than $4 per share, or $850 million....
![Why This Marijuana Stock Crashed 18.5% in August](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Why This Marijuana Stock Crashed 18.5% in August
Arizona's attorney general is suing Insys Therapeutics (NASDAQ: INSY) over its marketing of the fentanyl opioid spray, Subsys, and that news caused the company's shares to tumble 18.5% in August,....
![Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better
Investors have been wondering for a few years now when Gilead Sciences (NASDAQ: GILD) would spend some of its massive cash hoard and acquire a new company, and this week, Gilead put those wonders....
![Why Juno Therapeutics Shares Vaulted 46% Higher in August](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Why Juno Therapeutics Shares Vaulted 46% Higher in August
After Gilead Sciences (NASDAQ: GILD) scooped up competitor Kite Pharma (NASDAQ: KITE) for $11.9 billion and Novartis (NYSE: NVS) secured an approval from the Food and Drug Administration for....